NEW YORK, NY / ACCESSWIRE / March 23, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apyx Medical Corporation ("Apyx" or the Company") (NASDAQ:APYX).Investors who purchased Apyx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/apyx.
The investigation concerns whether Apyx and certain of its officers and/or directors have violated federal securities laws.
On March 16, 2020, Apyx announced that its financial statements for the twelve months ended December 31, 2018 and the quarterly statements for the three and nine months ended September 30, 2018 and three months ended March 31, 2019 could no longer be relied upon and would need to be restated. On this news, Apyx's stock price fell $0.23 per share, or 5.01%, to close at $4.36 per share on March 17, 2020.
If you are aware of any facts relating to this investigation, or purchased Apyx shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/apyx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC